WITHDRAWN: Publication status of 95 clinical trials of 3 COVID-19 vaccines developed by Chinese companies: An observational cohort study

Till Bruckner,Yixuan Chen,Carolina Cruz,Christie Ebube Dike,Belen Chavarria,Shiyu Chen,Ernest Dela Dzidzornu
DOI: https://doi.org/10.1101/2024.03.17.24304386
2024-05-24
Abstract:The authors have withdrawn their manuscript "Publication status of 95 clinical trials of 3 COVID-19 vaccines developed by Chinese companies: An observational cohort study" owing to two factors. First, the authors had failed to adequately de-duplicate the trials in the study cohort. Second, the authors had mistakenly assumed that most trials had been sponsored by the companies marketing the vaccines; this was not the case. Both mistakes were the sole responsibility of the corresponding author (TB). Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. A corrected and updated version of the original preprint will be published shortly under the title "Publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies: An observational cohort study".
Health Policy
What problem does this paper attempt to address?
The authors of this paper have retracted their research due to two errors: firstly, they failed to adequately remove duplicate trials from their study cohort; secondly, they mistakenly believed that the majority of trials were sponsored by vaccine-promoting companies, which was not the case. Therefore, the authors do not want this work to be cited as a reference for the project. They plan to publish a corrected and updated version with a new title "Publication Status and Disclosure Gaps of 71 Clinical Trials Evaluating the Safety and Efficacy of COVID-19 Vaccines Developed by Chinese Biopharmaceutical Companies: An Observational Cohort Study". Hence, the original paper aimed to track and analyze the publication status and transparency of clinical trials conducted on COVID-19 vaccines developed by Chinese companies, but it has been retracted due to data processing errors.